Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Furosemide 40mg/Pot chlor 600mg (pot 8mmol) MR tab
0202080K0AAABAB
|
Furosemide/potassium | Furosemide/potassium | Cardiovascular System | No data available |
|
Furosemide 4mg/5ml oral liquid
0202020L0AADEDE
|
Furosemide | Furosemide | Cardiovascular System | No data available |
|
Furosemide 500mg/5ml oral liquid
0202020L0AACRCR
|
Furosemide | Furosemide | Cardiovascular System | No data available |
|
Furosemide 50mg/5ml oral liquid
0202020L0AABXBX
|
Furosemide | Furosemide | Cardiovascular System | No data available |
|
Furosemide 6.5mg/5ml oral liquid
0202020L0AACICI
|
Furosemide | Furosemide | Cardiovascular System | No data available |
|
Furosemide 60mg/5ml oral liquid
0202020L0AACECE
|
Furosemide | Furosemide | Cardiovascular System | No data available |
|
Furosemide 80mg/5ml oral liquid
0202020L0AACBCB
|
Furosemide | Furosemide | Cardiovascular System | No data available |
|
Furosemide 80mg/8ml inj Minijet pre-filled syringes
0202020L0BIAGBS
|
Minjet furosemide | Furosemide | Cardiovascular System | No data available |
|
Furosemide 80mg/8ml inj pre-filled syringes
0202020L0AABSBS
|
Furosemide | Furosemide | Cardiovascular System | No data available |
|
Furosemide 8mg/5ml oral liquid
0202020L0AADDDD
|
Furosemide | Furosemide | Cardiovascular System | No data available |
|
Fusafungine 500micrograms/dose nsl/oromucosal spy sugar free
1202030D0AAABAB
|
Fusafungine | Fusafungine | Ear, Nose and Oropharynx | No data available |
|
Fusidic acid 2% gel
1310012F0AAACAC
|
Fusidic acid (Topical) | Fusidic acid | Skin | No data available |
|
Futibatinib 4mg tablets
0801050CWAAAAAA
|
Futibatinib | Futibatinib | Malignant Disease and Immunosuppression | No data available |
|
Fuzeon 108mg inj vials
0503010J0BBAAAA
|
Fuzeon | Enfuvirtide | Infections | No data available |
|
Fybogel Orange 3.5g effervescent granules
0212000J0BCAAAA
|
Fybogel (Lipid Lowering) | Ispaghula husk | Cardiovascular System | No data available |
|
Fybogel Orange 3.5g effervescent granules sachets SF
0106010E0BBABAH
|
Fybogel | Ispaghula husk | Gastro-Intestinal System | No data available |
|
Fybozest Orange 3.5g effervescent granules
0212000J0BBAAAA
|
Fybozest | Ispaghula husk | Cardiovascular System | No data available |
|
G & G Children's Fish Oil 500mg softgels capsules
090601100BBGUA0
|
Proprietary compound preparation BNF 0906011 | Other vitamin A preparations 0906011 | Nutrition and Blood | No data available |
|
G & G Collagen Extra capsules
091000000BBXPBT
|
Proprietary compound preparation BNF 0910000 | Other compound vitamin/mineral formulation preparations | Nutrition and Blood | No data available |
|
G & G CoQ10 100mg capsules
091102000BBIMBA
|
Proprietary compound preparation BNF 0911020 | Other enzyme preparations 0911020 | Nutrition and Blood | No data available |
|
G & G Glucosamine with Chondroitin & Vitamin C capsules
091200000BFTFA0
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
G & G L-Arginine 500mg capsules
091101000BBHWCS
|
Proprietary compound preparation BNF 0911010 | Other amino acidandnutritional agent preparations | Nutrition and Blood | No data available |
|
G & G Magnesium citrate 100mg capsules
0905013F0BEAAAB
|
G & G (Magnesium citrate) | Magnesium citrate | Nutrition and Blood | No data available |
|
G & G MSM 500mg & Vitamin C 100mg capsules
091200000BFTKA0
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
|
G & G MSM 500mg capsules
091200000BFTLA0
|
Proprietary compound preparation BNF 0912000 | Other health supplement preparations | Nutrition and Blood | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.